Argen X Stock Quote ARGX - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

348.50

Bid

343.10

Ask

352.50

Volume

29,188

343.90 Day's Range 354.70

271.00 52 Week Range 494.10

Market Cap

19.923B

Previous Close

349.30

Open

349.30

Last Trade

348.5

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

60,071

Shares Outstanding

57,169,000

Dividend Yield

PE Ratio

-67.52

Earnings Per Share (EPS)

-5.16

Revenue

1.27B

Net Profit

-295.05M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.argenx.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1970

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 349.30 €. Over the last year, Argen X shares have traded in a share price range of 271.00 € to 494.10 €.

Argen X currently has 57,169,000 shares outstanding. The market capitalization of Argen X is 19.92 € billion. Argen X has a price to earnings ratio (PE ratio) of -67.52.

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024...

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP...

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with...

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of...

argenx to Present at Upcoming Investor Conferences

February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024...

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	10.7	3.16755476613	337.8	356.4	337.1	37255	346.08750819	DE
4	-16.7	-4.57283680175	365.2	369.2	334.7	39120	351.33209612	DE
12	-0.9	-0.257584430452	349.4	381.1	322.5	60071	357.74941441	DE
26	-94.3	-21.2962962963	442.8	475.8	271	66318	374.4629429	DE
52	-6.7	-1.88626126126	355.2	494.1	271	62452	397.84418883	DE
156	108.1	44.9667221298	240.4	494.1	201.4	65283	336.85346237	DE
260	237.1	212.836624776	111.4	494.1	93.05	80877	250.40191211	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CAUDCollective Audience Inc	$ 0.7327 (87.87%)	139.03M
DCPHDeciphera Pharmaceuticals Inc	$ 25.285 (72.59%)	39.68M
MULNMullen Automotive Inc	$ 4.47 (41.46%)	33.65M
HWHHWH International Inc	$ 2.52 (38.46%)	23.06M
BTOGBit Origin Ltd	$ 4.46 (34.34%)	396.42k
CLVRClever Leaves Holdings Inc	$ 1.59 (-61.31%)	615.22k
ADXNAddex Therapeutics Ltd	$ 8.00 (-50.31%)	123.03k
MFImF International Ltd	$ 1.5294 (-34.36%)	2.52M
TSDDGraniteShares ETF Trust GraniteShares	$ 17.00 (-31.73%)	1.16M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	$ 26.88 (-31.55%)	5.82M
TSLATesla Inc	$ 194.94 (15.84%)	163.83M
CAUDCollective Audience Inc	$ 0.7327 (87.87%)	139.03M
SINTSiNtx Technologies Inc	$ 0.0527 (30.45%)	138.53M
SOFISoFi Technologies Inc	$ 7.0899 (-9.91%)	112.19M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 9.42 (31.75%)	63.74M